AAP
IMDX

Ardsley Advisory Partners’s Insight Molecular Diagnostics IMDX Stock Holding History

Ardsley Advisory Partners’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-597
Closed -$29K – 155
2020
Q1 		$29K Buy
+597
New +$29.3K 0.01% 98

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BC
Blackcrane Capital Bellevue, Washington $16.3M AUM 19.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ardsley Advisory Partners's IMDX Position: Q2 2020 in Review

Ardsley Advisory Partners sold out of Insight Molecular Diagnostics (IMDX) in Q2 2020, closing a stake of 597 shares — an estimated $29K sold.

Ardsley Advisory Partners first reported a position in IMDX in Q1 2020 and held it in 1 quarter. The position peaked at $29K in Q1 2020. 66 funds tracked by Wall St. Rank hold IMDX as of Q2 2020.

  • Ardsley Advisory Partners reported no remaining Insight Molecular Diagnostics position as of Q2 2020 after selling out during the quarter.
  • Ardsley Advisory Partners sold 597 Insight Molecular Diagnostics shares in Q2 2020, an estimated $29K.
  • Ardsley Advisory Partners first reported a position in Insight Molecular Diagnostics in Q1 2020 and held it in 1 quarter.
  • Ardsley Advisory Partners's Insight Molecular Diagnostics position peaked at $29K in Q1 2020.
  • 66 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2020.

Based on Ardsley Advisory Partners's 13F filing for Q2 2020, filed 14 Aug 2020.